Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..
2021.
Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.
Barbet G, Nair-Gupta P, Schotsaert M, Yeung ST, Moretti J, Seyffer F, Metreveli G, Gardner T, Choi A, Tortorella D et al..
2021.
TAP dysfunction in dendritic cells enables noncanonical cross-presentation for T cell priming.. Nat Immunol. 22(4):497-509.
Aldridge BB, Barros-Aguirre D, Barry CE, Bates RH, Berthel SJ, Boshoff HI, Chibale K, Chu X-J, Cooper CB, Dartois V et al..
2021.
The Tuberculosis Drug Accelerator at year 10: what have we learned? Nat Med. 27(8):1333-1337.
Grover S, Engelhart CA, Pérez-Herrán E, Li W, Abrahams KA, Papavinasasundaram K, Bean JM, Sassetti CM, Mendoza-Losana A, Besra GS et al..
2021.
Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in Mycobacterium tuberculosis.. ACS Infect Dis. 7(1):141-152.
Sanders RW, Moore JP.
2021.
Virus vaccines: proteins prefer prolines.. Cell Host Microbe. 29(3):327-333.